Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Investor Day (2015)
6 slides from Zealand Pharma A/s's investor day presentation, 2015
Slide 1: Closing remarks including outlook and news flow
Closing remarks including outlook and news flow Zealand Pharma A/S page 1
Slide 2: From peptide to patient - A diligent growth strategy
From peptide to patient - A diligent growth strategy Advance proprietary medicines Focus on specialty disease areas Focus on taking select medicines all Strengthened focus on specialty the way to registration, leveraging disease areas with high relevance for expected revenues from out-licensed pepti
Slide 3: Expected event outlook: Out-licensed portfolio
Expected event outlook: Out-licensed portfolio 2015 2016 Q4 H1 H2 Lixisenatide (Lyxumia®) Quarterly reports on royalty revenue and status Lixisenatide: US regulatory decision by the FDA (Q3) Lixilan Planned regulatory submission by Sanofi in the US Planned regulatory submission by Sanofi in
Slide 4: Expected event outlook: Proprietary pipeline
Expected event outlook: Proprietary pipeline 2015 2016 Q4 H1 H2 Danegaptide Topline results from Phase II Proof-of-Concept trial (Q1) ZP1848 (GLP-2) Start dosing of patients in the Phase II Proof-of-Concept trial Clinical Phase II update ZP4207 rescue pen Initiate next stage of clinical develo
Slide 5: Zealand's portfolio – Indicative 12 months outlook
Zealand’s portfolio – Indicative 12 months outlook Product / indication Preclinical Phase I Phase II Phase III Reg Marketed Outlicensed products and partnered projects Lyxumia® (lixisenatide) - ex-US Type 2 diabetes Lixisenatide - US Type 2 diabetes Lixilan (lixisenatide/insulin glargine combination
Slide 6: Thank you for your attention!
Thank you for your attention! Zealand Pharma A/S page 6